Breast cancer, Secondary cancers
Results
Phase 2
This trial looked at a drug called vandetanib alongside a type of hormone therapy called fulvestrant.
It was for women who had been through the .
This trial was supported by Cancer Research UK. Women could join between 2015 and 2017. The team published the results in 2023.
You pronounce vandetanib as van-det-a-nib.
Recruitment start: 20 April 2015
Recruitment end: 31 October 2017
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Mark Beresford
Professor Robert Jones
AstraZeneca
Cancer Research UK
NCRI Breast Clinical Studies Group
Velindre NHS Trust
Centre for Trials Research, Cardiff University
This is Cancer Research UK trial number CRUK/13/029.
Last reviewed: 04 Mar 2026
CRUK internal database number: 11760
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
